Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Stephen Johnston, Anna Emde, Carlos H. Barrios, et al.
JNCI Cancer Spectrum (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 10

Showing 10 citing articles:

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1131-1140
Open Access | Times Cited: 25
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Drugs (2025)
Open Access | Times Cited: 1
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
Ilenia Migliaccio, Cristina Guarducci, Luca Malorni
Advances in experimental medicine and biology (2025), pp. 475-493
Closed Access
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer
Kaitlyn O'Keefe, Neelam V. Desai, Antoinette R. Tan
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 517-527
Open Access | Times Cited: 1
Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
Takayuki Kobayashi, Meiko Nishimura, Mari Hosonaga, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
The solution structure of macrocyclic glecaprevir and its conformational adaptation mechanism towards antitumor targets
Qi Wang, Xiong Zhang, Hongyu Xu, et al.
Journal of Molecular Structure (2024) Vol. 1321, pp. 139814-139814
Closed Access
Oncologic therapies and neutropenia
Brit Long, Alex Koyfman
The American Journal of Emergency Medicine (2024)
Closed Access
Metastatic breast cancer—Overview on the development of the treatment standards 2024
Christoph Thomssen, Tjoung‐Won Park‐Simon
Die Gynäkologie (2024) Vol. 57, Iss. 5, pp. 296-306
Closed Access
Dual Inhibitors of CDK4 /6 for Treating Cancer
Peter L. Toogood
(2024), pp. 319-337
Closed Access
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Patrick Neven, Lieke Dullens, Sileny Han, et al.
Translational Breast Cancer Research (2023) Vol. 4, pp. 31-31
Open Access | Times Cited: 1
Page 1

Scroll to top